Sclerodermatous graft-versus-host disease after donor leucocyte infusion.
Leucocyte infusion from the marrow donor is a new therapeutic option to avoid repeated bone marrow transplants in patients with recurrent leukaemia. The treatment is based on the fact that alloreactive donor immune cells may recognize and eliminate residual leukaemia cells. This phenomenon has been called graft-versus-leukaemia. We describe a patient who received donor leucocyte infusion for a relapsed chronic myeloid leukaemia after his second bone marrow transplant and developed sclerodermatous graft-versus-host disease.
Jones-Caballero
M
M
Ambulatorio Hermanos Sangro, Area 1 de Salud de Madrid, Spain. derma/princesa@hup.es
Fernández-Herrera
J
J
Córdoba-Guijarro
S
S
Daudén-Tello
E
E
García-Díez
A
A
D000328:Adult; D006086:Graft vs Host Disease / Q000209:etiology*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D017708:Leukocyte Transfusion / Q000009:adverse effects*; D008297:Male; D012595:Scleroderma, Systemic / Q000209:etiology* / Q000473:pathology